Skin lesions may provide a clue to diagnosis in a patient with persistent fever and history of recent travel.

The aim of this study is to identify persistent symptoms in unvaccinated community-managed patients following COVID-19 infection.

A man aged 60 years presented with an irregularly shaped erythematous scalp plaque with a 5 cm diameter.

Growing evidence shows that lifestyle interventions are an effective component of management for patients with mental illness to improve mental health, physical health and quality of life.

There is a need to enhance aged care exposure for general practice registrars in ways that build on the competence of registrars and the trust in registrars by older patients and supervisors.

General practitioners are well positioned to take a comprehensive approach to the management of functional decline in older people, aided by a range of funded programs.

Young people experience higher rates of sexually transmissible infections and lower screening rates than the general population in Australia.

Medicare Benefits Schedule rules regarding sleep study eligibility have recently changed and incorporate validated questionnaires of obstructive sleep apnoea risk and subjective sleepiness.

MND is a group of neurodegenerative disorders best managed using a multidisciplinary approach, with the general practitioner as an integral part of the team.

Botulinum neurotoxin is an effective treatment for various movement disorders that are disabling and frequently under-recognised.

The enhanced Residential Medication Management Review program will address barriers and support general practitioners to make medication changes for older Australians.

Although not all women undergoing mastectomy will desire or choose breast reconstruction, it is important that all women have the opportunity to make an informed choice.

How should GPs and patients prioritise which preventive health activities to undertake?

Prescribing drugs to reduce the risk of cancer is a new development in primary cancer prevention.

For the detection of early COVID-19 disease, RCPA supports the use of molecular tests for SARS-CoV-2 and strongly opposes the introduction of COVID-19 IgG/IgM rapid tests for this purpose.